Plovdiv

• Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended
  2022-502899-23-00 5 2024-04-23 Hepatic Encephalopathy (OHE)
• Multi-center study of a fentanyl nasal spray compared with placebo nasal spray for postoperative pain management. Ended
  2024-519625-38-00 5 2024-04-14 Postoperative pain relief
• A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi … Ended
  2022-501421-20-00 5 2024-04-09 Gout with hyperuricemia
• A Phase 3 study to assess efficacy and safety of oral tebipenem compared to IV imipenem-cilastatin in adults with cUTI/AP Ended
  2023-503785-22-00 5 2024-03-25 complicated urinary tract infection (cUTI) or acute pyelonephritis (AP
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 4 2024-03-13 Heart Failure
• Functional Constipation: Linaclotide versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, with Functional Constipation (FC) Ended
  2022-501946-31-00 5 2024-02-29 Functional Constipation
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)
• A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with … Ended
  2022-501310-57-00 4 2024-02-05 Endometriosis related pain
• A study evaluating the effects of GLPG3667 given as oral treatment in adults with active systemic lupus erythematosus. Ended
  2023-503183-16-00 4 2024-01-16 Systemic Lupus Erythematosus
• Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis Ended
  2023-503790-37-00 5 2024-01-09 Post-Menopausal Osteoporosis
• Functional Constipation: A Phase 2 Dose Finding Study Evaluating the Safety and Efficacy of Linaclotide in Pediatric Subjects 6 Months to Le … Ended
  2022-501947-34-00 4 2023-12-05 Functional Constipation (FC)
• Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended
  2022-502208-64-00 4 2023-11-25 Asthma
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLAN … Ended
  2023-505050-18-00 6 2023-11-16 Axial spondyloarthritis
• A study to see how well PLS240 works in treating secondary hyperparathyroidism, and how safe it is, in end stage kidney disease participants … Ended
  2023-504338-24-00 5 2023-11-09 ESKD participants with history of secondary hyperparathyroidism (SHPT)
• A clinical trial to investigate efficacy and safety of NT 201 injections compared with placebo injections in participants aged 18 years and … Ended
  2022-501461-52-00 4 2023-10-17 Moderate to severe chronic peripheral neuropathic pain (PNP) due to po
• A study to learn how gadoquatrane moves into, through, and out of the body and how safe it is in children aged 0 to less than 18 years, who … Ended
  2022-501883-17-00 5 2023-10-16 Contrast enhancement in magnetic resonance imaging in children
• A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Parti … Ended
  2022-500568-37-00 5 2023-10-11 Masseter Muscle Prominence
• A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult … Ended
  2022-502552-31-00 4 2023-10-03 Relapsing Forms of Multiple Sclerosis
• A study to compare how well gadoquatrane works and its safety with an already available contrast agent for MRI in people with known or suspe … Ended
  2022-501884-41-00 5 2023-09-29 Contrast enhancement in magnetic resonance imaging for assessment of c
• BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria Ended
  2024-514764-72-00 5 2023-09-27 Chronic Urticaria
• A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended
  2023-503576-25-00 5 2023-09-22 Severe Hypertriglyceridemia
• A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno … Ended
  2022-501885-24-00 5 2023-09-20 Contrast enhancement in magnetic resonance imaging for assessment of n
• A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o … Ended
  2023-509833-38-00 5 2023-09-20 Birch Pollen-induced Allergic Rhinoconjunctivitis

Showing 337–360 of 417 trials